The gene therapy company is undergoing a restructure that will reduce headcount by 65%, or 300 roles. Those cuts include the recent sale of a Massachusetts manufacturing facility to Genezen. The restructure is expected to be complete in the fourth... — read more
still around, no issues, small co...
very small - we all know each other